TXA Soaked Gelatin Sponge to Reduce Rectus Sheath Hematoma After C.S. in Patients Using Warfarin

Study Overview
=================
Brief Summary
-----------------
The aim of this randomized controlled study is to demonstrate the effect of Local application of TXA impregnated in a gelatin sponge in reducing Rectus sheath hematoma formation in patients treated with warfarin following cesarean section.

Detailed Description
-----------------
The study will include (63) pregnant women attending for cesarean delivery who will receive anticoagulation (warfarin) postnatally. Patients included in this study will be subjected to: - Informed consent: patients representing the study population will be counselled about the intervention and informed written consent will be taken. Consenting patients will be subjected to the following: 1. Detailed personal, obstetric and medical and surgical history. 2- Examination: General Examination. Vital signs: Blood pressure, pulse and temperature. Weight, height, BMI. Abdominal examination for assessment of fundal level. 3. Laboratory Investigations Preoperatively CBC, Coagulation Profile, Blood Chemistry. 5. Abdominal Ultrasound: in order to assess the following: a. Gestational age determination. c. Placental site. CS will be done by Senior Obstetricians, Using Standard CS technique, with visceral and parietal peritoneum re-approximation and insertion of a passive intraperitoneal drain. Fascial closure will be done using continuous slowly absorbable sutures. Meticulous hemostasis will be achieved using monopolar cauterization. An active drain (Hemovac®) will be applied in the space between anterior rectus sheath and the rectus abdominis muscle in all patients. Patients will be randomly assigned into three groups Randomization is done by computer generated random numbers in opaque envelops. Group 1: (21) patients will have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) each sponge will be soaked with one ampoule and applied between the anterior rectus sheath and the rectus abdominis muscle, one sponge on each muscle. Group 2: (21) patients will have 2 Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) Not impregnated with Tranexamic acid applied locally using the same method as the previous group. Group 3: (21) patients will have Neither Gelatin Sponge nor Tranexamic acid applied. Follow up patients for vital signs and manifestations of allergic reactions in the immediate post operative period. The intraperitoneal drain will be removed after 24 hours in all groups. While the (Hemovac®) drain will be removed after achieving target INR in all groups. All Patients will be receiving bridging anticoagulation using LMWH(Enoxaparin) alone for 3 days in therapeutic doses (1mg/kg twice daily) to be initiated 12 hours after Surgery in most cases.Then Warfarin will be added on post operative day 3. LMWH will be withdrawn after achieving target INR. Then comparison between the three groups regarding Hemovac® Drain output in cc per day till achieving Target INR Levels for all patients. Ultrasound assessment of rectus sheath hematoma if present after achieving Target INR Levels for all patients.

Official Title
-----------------
The Effect of Using Tranexamic Acid Soaked Absorbable Gelatin Sponge in Reducing Rectus Sheath Hematoma Formation After Cesarean Section in Patients Using Warfarin Compounds

Conditions
-----------------
Rectus Sheath Hematoma, Cesarean Section

Intervention / Treatment
-----------------
* Drug: Tranexamic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: o Pregnant women attending for elective CS. Women on antenatal anticoagulation ( LMWH , UFH , Fondaparinux ) for conditions such as : Prosthetic Valve , DVT , Pulmonary embolism , Dural sinus thrombosis , AF. Pregnant Women with indication for postnatal warfarin anticoagulation( Prosthetic Valve , DVT , Dural Sinus Thrombosis , AF , Pulmonary embolism ) Age between 20-40 years. Pregnancies between 37 and 39 weeks BMI between (18.5 - 30.0) Exclusion Criteria: o Pregnancy with risk of obstetric hemorrhage such as abnormally invasive placenta, placenta previa, placental abruption. Women with Renal and Hepatic failure Women with bleeding diathesis for reasons other than warfarin anticoagulation therapy Women with known allergy to Tranexamic acid Anemia Hb below 8g/dl

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gelatin Sponges soaked with TXA<br>21 patients will have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml) each sponge will be soaked with one ampoule and applied between the anterior rectus sheath and the rectus abdominis muscle, one sponge on each muscle. | Drug: Tranexamic acid<br>* have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)<br>* Other names: Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India);|
| Experimental: Gelatin Sponges<br>2 Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) | Drug: Tranexamic acid<br>* have 2 pieces of Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India) (Size, 40 cm2) soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)<br>* Other names: Gelatin Sponges (SURGISPON®; AEGIS LIFESCIENCES, India);|
| No Intervention: NO SPONGE<br>21 patients will have no sponge inserted 10 ml of saline | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rectus sheath hematoma formation | Rectus sheath hematoma formation detected by Ultrasound | 1 weeks | 
| Excessive bleeding from subrectus space | amount of blood coming out of the drains | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thromboembolic manifestations | DVT | 1 weeks | 
| Blood transfusion | ml | 1 week | 
| The need for surgical evacuation of rectus sheath hematoma | surgery | 1 week |